Tenax因超过180万美元的内部购买而上涨

2026-08-25 19:36

Cardiopulmonary drug developer Tenax Therapeutics (TENX) added nearly 13% in the premarket trading on Tuesday after Adar1 Capital Management, one of its key shareholders, bought more than $1.8M worth of company shares.
According to a regulatory filing on Monday, the Austin, Texas-based investment manager, which holds over a 10% stake in Tenax (TENX), bought more than 1.0M Tenax (TENX) shares for an average price of $1.77 each, increasing its stake in the company by roughly 27%.
Adar1 holds over 4.7M company shares after the transaction, which took place on Thursday after Tenax (TENX) lost nearly 90% of its value earlier this month following a late-stage trial setback for its lead asset, TNX-103, targeted at patients with a certain type of pulmonary hypertension.
However, Wall Street analysts remain bullish on the stock, with seven Buy ratings, including six Strong Buys.

More on Tenax Therapeutics